Spero Therapeutics, Inc. (SPRO) Operating income 2016–2025
Spero Therapeutics, Inc. (SPRO) annual operating income history from SEC filings — each fiscal year as reported.
$6.3MFY2025 · since FY2016: -$33.2M → $6.3M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $6.3M | +108.6% |
| FY2024 | -$73.4M | -441.5% |
| FY2023 | $21.5M | +150.9% |
| FY2022 | -$42.2M | +52.0% |
| FY2021 | -$88.0M | -11.2% |
| FY2020 | -$79.1M | -25.1% |
| FY2019 | -$63.2M | -47.7% |
| FY2018 | -$42.8M | -2.6% |
| FY2017 | -$41.7M | -25.6% |
| FY2016 | -$33.2M | — |
Source: SEC XBRL filings · For reference only · Not investment advice